Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.
Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.
Aura Biosciences (NASDAQ:AURA) reported Q2 2026 results and a strategic refocus on ocular oncology centered on belzupacap sarotalocan (bel-sar). The Phase 3 CoMpass trial in early choroidal melanoma is fully enrolled with 108 patients, exceeding target, with 15‑month topline data expected in 2H 2027 under an FDA Special Protocol Assessment.
Interim Phase 1b/2 data in NMIBC showed 81% objective response and 69% complete response at 3 months, with all evaluable patients at 9–12 months disease‑free and only Grade 1 treatment‑related adverse events, though this program is being deprioritized. Aura is increasing investment in bel-sar programs for choroidal metastases and ocular surface cancers, executing a 20% workforce reduction and restructuring that, with disciplined capital allocation, is expected to extend its projected cash runway into 1H 2029.
As of June 30, 2026, cash, cash equivalents and marketable securities were $323.8 million. Q2 research and development expenses were $30.7 million and general and administrative expenses $17.3 million, leading to a net loss of $45.6 million versus $27.0 million a year earlier. Aura expects $2.9–$3.2 million of restructuring charges, largely for employee-related costs, with the plan substantially complete by Q3 2026.
Aura Biosciences (NASDAQ:AURA) appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
Bender is former CEO and President of Day One Biopharmaceuticals, where he oversaw approval and launch of OJEMDA for pediatric low-grade glioma and the company’s approximately $2.5 billion acquisition by Servier in 2026. Aura is advancing bel-sar, with enrollment complete in the Phase 3 CoMpass trial and progression toward potential regulatory approval as a frontline, vision-preserving treatment for early choroidal melanoma.
Aura Biosciences (NASDAQ:AURA) completed enrollment of 108 patients in the Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) as frontline therapy for early choroidal melanoma.
Topline data for the 15‑month primary endpoint are expected in the second half of 2027. The global, randomized trial compares bel-sar with sham control under an FDA Special Protocol Assessment and has FDA/EMA orphan and FDA Fast Track designations.
Aura Biosciences (NASDAQ:AURA) granted inducement equity awards to new CEO and President Natalie Holles on May 19, 2026 under Nasdaq Rule 5635(c)(4).
The package includes options for 2,169,103 shares at $7.39, 600,118 RSUs, and 553,844 PRSUs, all subject to multi‑year time and, for PRSUs, performance vesting conditions.
Aura Biosciences (NASDAQ:AURA), a clinical-stage biotech developing precision therapies for solid tumors, will participate in two May 2026 investor conferences.
Management will host fireside chats at the H.C. Wainwright BioConnect Conference and the TD Cowen Oncology Innovation Summit, with live webcasts and 90-day replays on the company’s investor website.
Aura Biosciences (NASDAQ:AURA) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $114.7 million on March 31, 2026, plus $280.8 million in net proceeds from an oversubscribed equity offering, extending cash runway into 2H 2028.
The Phase 3 CoMpass trial in early choroidal melanoma is expected to complete enrollment by mid-2026, with topline data in 2H 2027. Natalie Holles was appointed CEO and President. Net loss rose to $33.7 million, driven by higher R&D and G&A expenses.
Aura Biosciences (Nasdaq: AURA) closed an underwritten public offering on May 5, 2026, selling 46,099,650 common shares (including full exercise of the underwriters' option) and pre-funded warrants to purchase up to 3,800,000 shares.
Securities sold at $6.00 per share and $5.99999 per pre-funded warrant, producing approximately $299.4 million gross proceeds before underwriting discounts, commissions and offering expenses.
Aura Biosciences (Nasdaq: AURA) priced a public offering to sell 39,591,000 shares and pre-funded warrants for up to 3,800,000 shares, at $6.00 and $5.99999 respectively, with gross proceeds expected of $260.3 million. Aura granted underwriters a 30-day option for up to 6,508,650 additional shares. The offering is expected to close on or about May 5, 2026. Aura intends to use approximately $205.1 million of net proceeds, plus existing cash, to advance clinical programs and registration-enabling activities for bel-sar, and to repurchase up to 6,922,870 shares from Matrix at $5.64 per share.
Aura Biosciences (Nasdaq: AURA) launched an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common stock. Aura also intends to give underwriters a 30-day option to buy up to an additional 15% of the offering.
The offering is subject to market conditions and will be made from a Form S-3 shelf registration declared effective April 5, 2024; final terms will appear in a prospectus supplement filed with the SEC.
Aura Biosciences (NASDAQ: AURA) appointed Natalie Holles as CEO, President and board member effective April 30, 2026, replacing founder Elisabet de los Pinos. The company reports its Phase 3 CoMpass trial of belzupacap sarotalocan for early choroidal melanoma is nearing enrollment completion with 86 patients enrolled and >25 more scheduled or identified through May 2026. Aura reiterates enrollment completion by mid-2026 and topline CoMpass data in H2 2027.